ProfileGDS5678 / 1459650_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 55% 55% 51% 55% 63% 54% 55% 57% 55% 51% 55% 55% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3989554
GSM967853U87-EV human glioblastoma xenograft - Control 23.3810955
GSM967854U87-EV human glioblastoma xenograft - Control 33.3842455
GSM967855U87-EV human glioblastoma xenograft - Control 43.1743251
GSM967856U87-EV human glioblastoma xenograft - Control 53.3340555
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8608163
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4173154
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3595255
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4228557
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3722655
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2197151
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3205155
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3733555
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3733955